

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Monotrim 10 mg/ml Oral Suspension

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains 10 mg trimethoprim.

Excipients with known effect:

Each ml of this medicine contains 408 mg sorbitol, 1.3 mg methyl parahydroxybenzoate and 0.85 mg sodium.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Oral suspension.

White, homogenous suspension with odour of aniseed.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Treatment of infections caused by trimethoprim-sensitive organisms including urinary and respiratory tract infections and prophylaxis of recurrent urinary tract infections.

4.2 Posology and method of administration

Posology

1. Treatment of respiratory and urinary tract infections:

Adults and children over 12 years: The usual dosage is 200 mg (four 5 ml spoonfuls) twice daily for 7-10 days.

Paediatric population (under 12 years): Based on 6 mg/kg/day in two divided dosages as follows:

6 weeks to 5 months: 25 mg (half a 5 ml spoonful) twice daily for 7-10 days.

6 months to 3 years (8-15 kg): 25-50 mg (half to one 5 ml spoonful) twice daily for 7-10 days.

4-7 years (15-25 kg): 50-75 mg (one to one-and-a-half 5 ml spoonfuls) twice daily for 7- 10 days.

8-12 years (25-40 kg): 75-125 mg (one-and-a-half to two-and-a-half 5 ml spoonfuls) twice daily for 7-10 days.

The first dosage on the first day can be doubled.

2. Prophylaxis of recurrent urinary tract infection:

Adults and children over 12 years: The usual dose is 100 mg (two 5 ml spoonfuls) at night.

An extra 100 mg may be taken in the morning, if necessary.

Paediatric population under 12 years: 2.5 mg/kg/day once daily in the evening.

3. Dosage in renal impairment:

eGFR (ml/min)	Dosage advised
Over 30	normal
15-30	normal for 3 days then half dose
Under 15	half normal dose

Monitoring of renal function and serum electrolytes should be considered particularly with longer term use, in patients with impaired renal function.

Trimethoprim should only be initiated and used in dialysis patients under close supervision from specialists in both infectious disease and renal medicine. Trimethoprim is removed by dialysis.

Monitoring trimethoprim plasma concentration may be considered with long term therapy but the value of this in individual cases should first be discussed with specialists in infectious disease and renal medicine.

Method of administration

For oral use.

4.3 Contraindications

Hypersensitivity to trimethoprim or to any of the excipients.

Pregnancy, premature infants and neonates under 6 weeks, blood dyscrasias

4.4 Special warnings and precautions for use

Trimethoprim may cause a depression of haemopoiesis. During long-term therapy haematology should be monitored regularly in order to detect possible pancytopenia.

Particular attention should be paid to patients showing a tendency to folate deficiency, which may be aggravated by the use of this agent. If there is evidence of folic acid deficiency, calcium folinate should be administered and adequate response should be ensured by appropriate haematological monitoring. This treatment may not be effective unless trimethoprim is discontinued. In patients with impairment of renal function, care should be taken to avoid accumulation. Monitoring of renal function and serum electrolytes should be considered particularly with longer term use.

Trimethoprim should only be initiated and used in dialysis patients under close supervision from specialists in both infectious disease and renal medicine.

Special monitoring of serum electrolytes should be performed in risk patients due to risk of hyperkalaemia. See section 4.8.

Blood glucose should be monitored if used concomitantly with repaglinide (see section 4.5).

Elevations in serum potassium have been observed in some patients treated with trimethoprim. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, poorly controlled diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, renin angiotensin system inhibitors (eg: ACE inhibitors or renin angiotensin receptor blockers), or those patients taking other drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the above-mentioned agents is deemed appropriate, monitoring of serum potassium is recommended (see section 4.5).

Excipients

This medicine contains 2,04 g sorbitol in each 5 ml which is equivalent to 408 mg/ml.

Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.

This medicine contains methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).

This medicine contains less than 1 mmol sodium (23 mg) per ml oral suspension, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interactions

Folate antagonists and anticonvulsants: Trimethoprim may induce folate deficiency in patients predisposed to folate deficiency such as those taking folate antagonists or anticonvulsants.

Bone marrow depressants: Trimethoprim may increase the potential for bone marrow aplasia. Cytotoxics such as azathioprine, mercaptopurine, methotrexate, increase the risk of haematological toxicity when given with trimethoprim.

Phenytoin and Digoxin: Careful monitoring of patients treated with digoxin or phenytoin is advised as trimethoprim may increase plasma concentration of digoxin and phenytoin by increasing their elimination half-life.

Diuretics: In elderly patients concurrently taking diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Rare cases of hyponatraemia have been reported in patients treated with trimethoprim and potassium sparing diuretics and/or thiazide diuretics.

Concomitant use of drugs that may increase serum potassium levels may lead to a significant increase in serum potassium. Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, renin-angiotensin system inhibitors (eg: ACE inhibitors or renin angiotensin receptor blockers) and other potassium increasing substances (eg: heparin). Monitoring of potassium should be undertaken as appropriate (see section 4.4).

Ciclosporin: Ciclosporin may increase nephrotoxicity of trimethoprim.

Anticoagulants: The anticoagulatory effect of warfarin and other coumarins may be increased when taken together with trimethoprim.

Procainamide: Trimethoprim increases plasma concentration of procainamide.

Lamivudine: Trimethoprim may increase the plasma concentration of lamivudine.

Oestrogens: Trimethoprim may possibly reduce the contraceptive effect of oestrogens.

Oral typhoid vaccine: This is inactivated by concomitant administration of anti-bacterials.

Pyrimethamine: The anti-folate effect may be increased if there is concomitant administration with trimethoprim.

Dapsone: Plasma concentrations of trimethoprim and dapsone may increase when taken together.

Repaglinide: Trimethoprim may enhance the effect of repaglinide (see section 4.4).

4.6 Fertility, pregnancy and lactation

Pregnancy

Trimethoprim should not be used during pregnancy.

Breast-feeding

Trimethoprim is excreted in breast milk. This should be kept in mind when considering administration to lactating women.

4.7 Effects on ability to drive and use machines

Monotrim 10 mg/ml Oral Suspension has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The frequencies of the undesirable effects listed below are not known (cannot be estimated from the available data).

Infections and infestations

Aseptic meningitis.

Blood and lymphatic system disorders

Depression of haemopoiesis (see sections 4.4 and 4.5).

Immune system disorders

Hypersensitivity, anaphylaxis.

Metabolism and nutrition disorders

Hyperkalaemia, especially in patients with impaired renal function and in elderly patients.

Eye disorders

Uveitis.

Gastrointestinal disorders

Nausea, vomiting, gastrointestinal upset.

Hepatobiliary disorders

Disturbances of liver enzyme values, jaundice.

Skin and subcutaneous tissue disorders:

Pruritus, skin rash, photosensitivity, angioedema.

Erythema multiforme, Stevens Johnson syndrome, toxic epidermal necrolysis

Musculoskeletal and connective tissue disorders

Myalgia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via

HPRA Pharmacovigilance

Website: www.hpra.ie

4.9 Overdose

Symptomatic treatment, gastric lavage and forced diuresis can be used. Depression of haematopoiesis by trimethoprim can be counteracted by intramuscular administration of calcium folinate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Trimethoprim and derivatives, ATC code: J01EA01

Trimethoprim is an antimicrobial agent.

Mechanism of action

The antimicrobial activity is due to selective inhibition of bacterial dihydrofolate reductase. *In-vitro* trimethoprim has effect on most Gram-positive and Gram-negative aerobic organisms, including enterobacteria such as *E. coli*, *Proteus*, *Klebsiellapneumoniae*, *Streptococcus faecalis*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Staphylococcus aureus*.

It has no effect on *Mycobacterium tuberculosis*, *Neisseria gonorrhoeae*, *Pseudomonas aeruginosa*, *Treponema pallidum*, or anaerobic bacteria.

5.2 Pharmacokinetic properties

Absorption and Biotransformation

Trimethoprim is absorbed rapidly and almost completely after oral administration and maximum plasma concentrations are reached after 1- 4 hours. Peak plasma concentration of about 1 microgram per ml has been reported after a single dose of 100 mg.

Half-life is about 12 hours in patients with normal renal function but up to 20-50 hours in anuric patients.

Distribution

Trimethoprim is rapidly and widely distributed to various tissues and fluids, including kidneys, liver, spleen, bronchial secretions, saliva and prostatic tissue and fluid. Tissue concentration is generally higher than plasma concentration.

Elimination

Trimethoprim is predominantly excreted in the urine in unchanged form. Urinary concentrations are generally well above the MIC of common pathogens for more than 24 hours after the last dosage.

5.3 Preclinical safety data

Not relevant (widely used in clinical practice).

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Carmellose sodium
Microcrystalline cellulose
Carboxymethylcellulose sodium
Ammonium glycyrrhizinate
Methyl parahydroxybenzoate (E218)
Sorbitol (E420)
Anise oil
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.
Discard any remaining solution 28 days after first opening.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Plastic bottle: 100 ml.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Taw Pharma (Ireland) Ltd
104 Lower Baggot Street
Dublin 2
D02 Y940
Ireland

8 MARKETING AUTHORISATION NUMBER

PA23081/014/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16 April 1982

Date of last renewal: 16 April 2007

10 DATE OF REVISION OF THE TEXT

